Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678414 | 0.93 | AR (0.41) | KCNH2ARFLT3KITPIM1 | |
| SCHEMBL2678433 | 0.88 | CYP1A1 (0.39) | — | |
| SCHEMBL2679129 | 0.86 | CYP11B1 (0.41) | — | |
| SCHEMBL2677924 | 0.85 | KDM1A (0.50) | HASPIN | |
| SCHEMBL2679030 | 0.81 | CYP1A1 (0.41) | — | |
| SCHEMBL2678416 | 0.81 | HSD17B10 (0.36) | SIGMAR1 | |
| SCHEMBL2679330 | 0.80 | HSD11B1 (0.41) | NSD2 | |
| SCHEMBL2678549 | 0.80 | ALOX5AP (0.43) | CCNT1CDK9 | |
| SCHEMBL2678616 | 0.79 | CYP11B1 (0.43) | — | |
| SCHEMBL2677627 | 0.78 | KDM1A (0.52) | HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759343-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI (FR) | 2012-08-09 | — | — | US | disclosed |
| US-8173669-B2 | Azabicycloalkane derivatives, preparation thereof and use thereof in therapy | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2118104-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008110699-A2 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202807-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | KCNH2 1409/4885AR 739/4885FLT3 72/4885 |
| US-20100035916-A1 | AZABICYCLOALKANE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF IN THERAPY | TPMT, CYP51A1, ABL1 | KCNH2 1409/4885AR 739/4885FLT3 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.